News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Cabozantinib plus nivolumab, ipilimumab improves PFS in advanced renal cell carcinoma
05 Jun 2026
byStephen Padilla
Adding cabozantinib to nivolumab and ipilimumab as first-line therapy, compared with placebo, results in prolonged progression-free survival (PFS) among untreated patients with advanced renal cell carcinoma (RCC), with no new safety signals seen, as shown by the results of the phase III COSMIC-313 study.








